---
title: "Thrombotic Thrombocytopenic Purpura (TTP)"
ocid: "ocds-h6vhtk-029113"
canonical_url: "https://d3tenders.com/contract/?ocid=ocds-h6vhtk-029113"
markdown_url: "https://d3tenders.com/contract/ocds-h6vhtk-029113.md"
json_url: "https://d3tenders.com/contract/ocds-h6vhtk-029113.json"
source: "Find A Tender Service"
current_stage: "Award"
buyer: "NHS ENGLAND - SPECIALISED COMMISSIONING"
published: "2021-02-08"
---

# Thrombotic Thrombocytopenic Purpura (TTP)

Buyer: NHS ENGLAND - SPECIALISED COMMISSIONING  
Current stage: Award  
OCID: ocds-h6vhtk-029113

[View canonical contract page](https://d3tenders.com/contract/?ocid=ocds-h6vhtk-029113)  
[Download OCDS JSON](https://d3tenders.com/contract/ocds-h6vhtk-029113.json)

## Summary

NHS England - Specialised Commissioning is proceeding with the award of contracts for the provision of services related to Thrombotic Thrombocytopenic Purpura (TTP) in London and parts of the South East (Kent, Surrey & Sussex), as well as the North West. This procurement is currently in the Award stage, following a negotiated procedure without prior publication. Key details include contract values of £20.7 million for the South East and £4.9 million for the North West, with contracts expected to be implemented shortly after the conclusion of this notice. The expected provision period is four years as part of an initiative aimed at improving patient outcomes for this serious blood disorder.

This tender presents significant opportunities for healthcare providers specialising in health and social work services, particularly those offering expertise in rare and complex medical conditions. Businesses that can demonstrate the capacity to provide specialist care, including effective diagnosis and management of TTP, will be particularly well-suited to compete. Additionally, those interested in expanding their service offerings across England will benefit from the expected future expressions of interest for further lots, which will be published in February 2021.

## Notice

Thrombotic Thrombocytopenic Purpura (TTP) is a serious blood disorder that results in blood clots forming in small blood vessels throughout the body. It affects the kidneys, heart and brain. If a patient is treated outside a specialist centre, mortality is 50%; in a specialist centre, it is 20%. There is also an appreciable acute morbidity, particularly in neurological disorders. The condition can be difficult to diagnose because initial presentation can be non-specific. Rapid treatment is essential for optimal outcomes and includes plasma exchange and a range of drugs. This disease primarily affects adults. Children are treated in paediatric haematology centres and are outside the scope of this process.

### Lot Information

Thrombotic Thrombocytopenic Purpura (TTP) - London and parts of the South East (Kent, Surrey & Sussex)

TTP is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient's blood is filtered and then put back into their body). The prevalence is 330 patients in England, with an acute incidence of 150 patients. There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are two centres in England where there are recognised services. The Commissioners are planning to initially enter into contract with two providers for a term of four years to provide cover for patients in (a) the North West and (b) London and parts of the South East. The reasons for this decision are: - The providers are the only two fully capable providers with recognised established services to meet the specification and will offer access to services, whilst new providers are identified through a competitive process to ensure access to services across England; - The two providers have full capacity and the necessary skills to deliver the service and have been assessed as meeting the service requirements and thus are eligible to be commissioned by NHS England and Improvement. Commissioners have undertaken a negotiated procedure without prior publication and have undertaken a due diligence assessment of the two Providers. They were required to complete a self-assessment questionnaire to ensure quality of service provision; which was approved as part of the strategic approach to commissioning these services and is in line with Commissioners internal governance mechanisms/processes to award these services. While the Commissioners are intending to award a contract for services across London and parts of the South East (Kent, Surrey & Sussex) based on the negotiated procedure without publication, they wish to seek further expression of interest, which is due to be published in February 2021, to secure provision for up to a further 7 Lots across England which includes South West, West Midlands, East Midlands, East of England, North East, Yorkshire and Humber and parts of the South East (Thames Valley, Hampshire and the Isle of Wight)*. Providers who are interested in these future opportunities will be required to register and respond separately to any future Notice as applicable, published in line with the regulations following conclusion of this notice. *Note, in securing the provision for parts of the South East, the Commissioners require the successful provider to work with the already established London provider. This will support shared care and improve local patient access to the service whilst ensuring availability of clinical expertise as appropriate.

Thrombotic Thrombocytopenic Purpura (TTP) - North West

TTP is a very rare, complex condition which can present as an acute life-threatening disorder that requires prompt diagnosis, early referral and effective immediate management in a centre with comprehensive provision and a multi-discipline approach. Specialist aftercare is also required. There is also a cohort of patients who have a congenital form of the disease who require ongoing apheresis (where a patient's blood is filtered and then put back into their body). The prevalence is 330 patients in England, with an acute incidence of 150 patients. There is a very high mortality rate for patients with this disease: if a patient is treated outside of a specialist centre, the death rate is 50%. There are two centres in England where there are recognised services. The Commissioners are planning to initially enter into contract with two providers for a term of four years to provide cover for patients in (a) the North West and (b) London and parts of the South East across England. The reasons for this decision are: - The providers are the only two fully capable providers with recognised established services to meet the specification and will offer access to services, whilst new providers are identified through a competitive process to ensure access to services across England; - The two providers have full capacity and the necessary skills to deliver the service and have been assessed as meeting the service requirements and thus are eligible to be commissioned by NHS England and Improvement. Commissioners have undertaken a negotiated procedure without prior publication and have undertaken a due diligence assessment of the two Providers, who were required to complete a self-assessment questionnaire to ensure quality of service provision; which was then approved as part of the strategic approach to commissioning these services and is in line with Commissioners internal governance mechanisms/processes to award these services. While the Commissioners are intending to award a contract for services across London and parts of the South East (Kent, Surrey & Sussex) based on the negotiated procedure without publication, they wish to seek further expression of interest, which is due to be published in February 2021, to secure provision for up to a further 7 Lots across England, which includes South West, West Midlands, East Midlands, East of England, North East, Yorkshire and Humber and parts of the South East (Thames Valley, Hampshire and the Isle of Wight)*. Providers who are interested in these future opportunities will be required to register and respond separately to any future Notice as applicable, published in line with the regulations following conclusion of this notice *Note, in securing the provision for parts of the South East, the Commissioners require the successful provider to work with the already established London provider. This will support shared care and improve local patient access to the service whilst ensuring availability of clinical expertise as appropriate.

### Procurement Information

The current pathway of care is disjointed and there was a need to review delivery in order to improve outcomes for patients. The current pattern shows patients receiving varying level of care with some patients treated in expert centres whereas others without access to expert advice. Due to the disjointed nature of the current TPP provision and the high mortality rate, the Prescribed Specialised Services Advisory Group (PSSAG) has requested that NHS England assume the commissioning responsibility for this disease, with the aim of establishing appropriate number of expert centres and clear and defined pathways to improve patient outcomes. To address the issues identified in the current provision, a new service delivery model and service specification has been developed, where the principle elements are: * Early diagnosis and commencement on apheresis. * Access to apheresis must be 24/7 * Patients require acute inpatient admission, which include ITU. * This disease is lifelong, and the expert centres must provide life monitoring and early intervention if the patient relapses. * A requirement for a treating and educative/outreach role to raise awareness of the disease, as the disease can present with non-specific symptoms in the early stages. The Commissioners recognise the importance of striking the right balance between geographical access, population and the need to maintain expertise and are working towards implementing the new delivery model.

## Key Details

| Field | Value |
| --- | --- |
| Publication source | Find A Tender Service |
| Latest notice | https://www.find-tender.service.gov.uk/Notice/002476-2021 |
| Notice type | Award Notice |
| Procurement type | Standard |
| Procurement category | Services |
| Procurement method | Limited |
| Procurement method details | Negotiated without publication of a contract notice |
| Tender suitability | Not specified |
| Awardee scale | Large |
| All stages | Award |

## Dates

| Field | Value |
| --- | --- |
| Publication date | 8 Feb 2021 |
| Submission deadline | Not specified |
| Future notice date | Not specified |
| Award date | 21 Dec 2020 |
| Contract period | Not specified |
| Recurrence | Not specified |

## Values

| Field | Value |
| --- | --- |
| Tender value | Not specified |
| Lots value | Not specified |
| Awards value | Not specified |
| Contracts value | £25,600,000 |

## Status

| Field | Value |
| --- | --- |
| Tender status | Complete |
| Lots status | Not specified |
| Awards status | Active |
| Contracts status | Active |

## Buyer

| Field | Value |
| --- | --- |
| Main buyer | NHS ENGLAND - SPECIALISED COMMISSIONING |
| Locality | LONDON |
| Post town | South East London |
| Postcode | SE1 6LH |
| Country | England |
| ITL 1 | TLI London |
| ITL 2 | TLI4 Inner London - East |
| ITL 3 | TLI44 Lewisham and Southwark |
| Local authority | Southwark |
| Electoral ward | St George's |
| Westminster constituency | Bermondsey and Old Southwark |
| Delivery location | TLD North West (England), TLI London, TLJ South East (England) |

## Supplier

| Field | Value |
| --- | --- |
| Number of suppliers | 2 |
| Supplier names | LIVERPOOL UNIVERSITY HOSPITALS NHS FOUNDATION TRUST; UNIVERSITY COLLEGE LONDON HOSPITALS NHS FOUNDATION TRUST |

## CPV Codes

### Divisions

- 85 - Health and social work services

### Codes

- 85000000 - Health and social work services
- 85100000 - Health services

## Release History

- 8 Feb 2021 at 13:35 - Award - Award Notice - https://www.find-tender.service.gov.uk/Notice/002476-2021

## Notice URLs

- https://www.ardengemcsu.nhs.uk/

## Provenance

This Markdown file is an alternate public rendering of the D3 Tenders contract record. The canonical page is https://d3tenders.com/contract/?ocid=ocds-h6vhtk-029113. The underlying structured data is available as OCDS JSON at https://d3tenders.com/contract/ocds-h6vhtk-029113.json.